Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
National Inst. of Pharma Education and Research (NIPER) EGFR compound 18i
- Development stage
- Unknown
- Lead developer
- National Institute of Pharmaceutical Education and Research
01
Overview
National Inst. of Pharma Education and Research (NIPER) EGFR compound 18i: sourced facts only. name: "Further, compound 18i demonstrated a remarkable inhibition of EGFR kinase, with an IC50 concentration of 42.3 nM." [PMID:39088978]; target: "Further, compound 18i demonstrated a remarkable inhibition of EGFR kinase, with an IC50 concentration of 42.3 nM." [PMID:39088978]; developer: "Department of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India." [PMID:39088978]
02
Targets
Beyond the preview
Go deeper on National Inst. of Pharma Education and Research (NIPER) EGFR compound 18i.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on National Inst. of Pharma Education and Research (NIPER) EGFR compound 18i.